Allen Mooney & Barnes Investment Advisors LLC Has $639,000 Stock Position in Stryker Co. (NYSE:SYK)

Allen Mooney & Barnes Investment Advisors LLC grew its stake in shares of Stryker Co. (NYSE:SYK) by 5.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,715 shares of the medical technology company’s stock after acquiring an additional 94 shares during the period. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Stryker were worth $639,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker in the 4th quarter valued at $25,000. Capital A Wealth Management LLC bought a new stake in shares of Stryker in the fourth quarter valued at about $26,000. Rakuten Securities Inc. grew its stake in shares of Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new position in Stryker during the fourth quarter worth about $30,000. Finally, City Holding Co. raised its stake in Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on SYK shares. BTIG Research set a $403.00 target price on shares of Stryker and gave the stock a “buy” rating in a research report on Monday, April 14th. Evercore ISI reduced their price target on Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research report on Friday, May 2nd. Citigroup reaffirmed a “buy” rating and issued a $455.00 price objective (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. Truist Financial increased their target price on Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, May 5th. Finally, Roth Mkm boosted their price target on Stryker from $405.00 to $456.00 and gave the company a “buy” rating in a research note on Friday, May 2nd. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $427.30.

Stryker Stock Performance

Shares of Stryker stock opened at $381.03 on Thursday. The stock has a market cap of $145.43 billion, a price-to-earnings ratio of 49.10, a P/E/G ratio of 2.93 and a beta of 0.91. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company’s fifty day moving average is $371.23 and its 200 day moving average is $375.95.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the previous year, the company posted $2.50 EPS. The business’s revenue was up 11.9% on a year-over-year basis. Sell-side analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date is Monday, June 30th. Stryker’s dividend payout ratio is currently 45.41%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the sale, the director now owns 3,417,326 shares of the company’s stock, valued at approximately $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.